We’re all unique
So is Aummune
tri-functional aptamer drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses
Additionally, Aptamers exhibit several key advantages
Lower costs of
Individually tailored tri-functional aptamers
cells, leading to
tumor cell lysis.
the two strands and induces Antigen
Presenting Cells stimulation through
Toll-Like Receptor 9
ability to bind the patient’s cancer cells
and induce cancer cell death while
avoiding effects on healthy tissue.
to every patient
and negative selection process on a
patient’s tumor and healthy cell samples,
to achieve a tumoricidal yet safe effect
Aummune’s unique therapeutic edge
approach to treat
No wasted effort
Aummune lead program, AM003, has demonstrated efficacy and safety in several animal models and, upon completion of its preclinical program and positive interactions with regulatory authorities, will start a Phase 1 clinical study in the first half of 2022.
The First-in –Human study will enroll patients with locally advanced and metastatic solid tumors.
Mr. Weinand is the former CEO of Bayer Pharma AG, and is an experienced business leader with over 25 years of experience in the pharmaceutical industry. During his career, he has held various responsibilities in general management, commercial, operational and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the United States, for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi. He has also lead the launch and marketing of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, and respiratory and inflammatory diseases. He is currently Chairman of the Board of Replimune (REPL) and Executive Chairman of the Board of Ziel BioPharma. Mr. Weinand earned an MS in pharmacology and toxicology from Long Island University, New York, and a BA in biology from Concordia College, New York.
Dr. Irit Carmi-Levy
Ph.D. - CSO
Prior to joining Aummune, Dr. Carmi-Levy served as a Project Director in BioLineRx. She is a drug development expert and an immunologist by training. Dr. Carmi-Levy performed postdoctoral research at the Curie Institute and earned her PhD in Biochemistry and Molecular Biology from the Hebrew University.
Mr. Marius Nacht
Mr. Nacht is a cofounder of a dozen tech and biotech companies and of multiple VC funds. He is also a direct investor in numerous companies and VC funds. In 1993, Mr. Nacht co-founded the cybersecurity firm Check Point Software Technologies (NASDAQ: CHKP) and held multiple executive roles as it went on to become a global pioneer in the cybersecurity industry. He recently stepped down from his position as chairman of Check Point to focus on his initiatives in the healthcare industry.
Mr. Nacht holds a BSc in Physics and Mathematics (cum laude) from the Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiot technological academy and a captain in the Israeli Air Force.
Dr. Karen Smith
MD, PhD, MBA, LLM - Director
Dr. Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor. Her breadth of experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions including FDA, EMA, TGA, ANVISA, and PMDA; leading to product launches across diverse therapeutic areas including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, Dr. Smith’s successful record of business development includes acquisitions, divestitures, and partnership deals.
Dr. Smith has held various President, CEO, and Chief Medical Officer roles over the past 20 years. She has built companies from the ground up and is a strong advocate for women in science and diversity in the boardroom. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca and Bristol Myers Squibb. Dr. Smith currently serves on the Board of Antares (ATRS), Sangamo Tx (SGMO),and Capstan Tx. Previously, Dr. Smith served on the board of Forward Pharma A/S (FWD), Sucampo (SCMP), and Acceleron (XLRN), each with a greater than $1 billion exit.
Dr. Nadav Navon
PhD, MBA – COO
Prior to joining Aummune, Dr. Navon was Intec Pharma’s Chief Operating Officer and was a key leader in the company’s establishment. He led the operations and development of a new drug delivery technology from invention through Phase III and built unique commercial manufacturing capabilities. Prior to Intec, he headed the analytical and QA operations at Sharon Laboratories, a company that develops and manufactures raw materials for the pharmaceutical and cosmetic industries. Prior to that, Dr. Navon led several R&D projects in the NNCR. Dr. Navon holds a PhD in chemistry and MBA from Ben-Gurion University.
Mr. Guy Neev
Mr. Neev has more than 20 years’ experience in executive level positions in the medical and high tech industries. He cofounded Aummune and Curesponse and served as the Chief Executive Officer of both companies. Previously, he served as the Chief Executive Officer of Check-Cap Ltd and Cappella Medical. During his time at Check-Cap he led the company from inception, through its successful initial public offering in the United States and listing of its securities on NASDAQ. He also held executive positions at Boston Scientific and led business development with St. Jude Medical in Israel before its acquisition by Abbott.
Yuri D. Shoshan
MBA - Director
Mr. Shoshan is and expert in early stage technology company building. He is currently the COO of 1E Therapeutics, and CEO of Augmanity, a private research lab. He was a Manager at McKinsey and Company and a Principal at Pitango VC, was the founding COO/CFO of BioLineRx, and served as CEO of Qualitas Health and a number of other early-stage medtech startups. Mr. Shoshan holds a BA in Economics and Mathematics from Columbia University and an MBA from the Harvard Business School.
Dr. Raanan Berger
MD, PhD - CMO
Dr. Berger is director of the Institute of Oncology at the Sheba Medical Center, Israel. He is a senior Oncologist and Radiotherapist, leading the genitourinary oncology program and heading the clinical research facility in the Institute of Oncology and Radiotherapy at Sheba, as well as running a basic and translational research lab studying molecular mechanisms in prostate and breast tumorigenesis.
Dr. Berger holds an MD and a PhD from Sackler Medical School at the Tel Aviv University, completed clinical training in Medical Oncology and Radiotherapy at Sheba and a postdoctoral fellowship at the Dana Farber Cancer Institute at Harvard Medical School.
Dr. Ido Bachelet
PhD - CTO & Co Founder
Dr. Bachelet is a recognized pioneer in therapeutic DNA nanotechnology and synthetic biology as well as a cofounder of multiple biotech and medical device companies including Sight Diagnostics, 1E Therapeutics and Wild Biotech. He holds a PhD in medical sciences from the Hebrew University, was a postdoctoral fellow at MIT and Harvard Medical School, and is the author of over 60 academic papers and patents.
Tel Aviv Medical Center (TAMC),
Sammy Ofer Building, Floor 10
Weizmann St 6, Tel Aviv-Yafo, ISRAEL